Quest Diagnostics has been awarded a contract by the U.S. Centers for Disease Control and Prevention – CDC – designed to assess the burden of hepatitis C virus – HCV – in the U.S. Quest will perform both HCV antibody testing and molecular RNA testing using HIPAA-deidentified “remnant” specimens randomly selected from clinical test specimens. The goal is to gain a better understanding of the burden of hepatitis C infection in the United States.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DGX:
- Quest Diagnostics and Scipher Medicine collaborate in rheumatoid arhritis
- Quest Diagnostics partners with Universal DX for colorectal cancer blood test
- Quest Diagnostics price target raised to $149 from $148 at JPMorgan
- Quest Diagnostics Declares Quarterly Cash Dividend
- Quest Diagnostics management to meet virtually with Oppenheimer